ProMining Therapeutics, Ltd. Announced a Collaboration With Roche for the
Discovery of Small Molecule Therapeutics for the Treatment of Type 2 Diabetes
Using ProMining's CavitIIRx Platform Technology
JERUSALEM, December 17, 2012
JERUSALEM, December 17, 2012 /PRNewswire/ --
ProMining Therapeutics, Ltd. today announced a new collaboration with Roche
(SIX: RO, ROG; OTCQX: RHHBY) in the field of type 2 diabetes mellitus. Under
the terms of the agreement, ProMining Therapeutics will use its CavitIIRx
platform to develop small molecule therapeutics for treatment of type 2
diabetes mellitus and will receive research based funding. Further details of
the agreement were not disclosed.
"We are pleased to have completed this agreement with Roche and are very
excited by the prospect of jointly delivering novel therapeutic oral small
molecules to patients suffering from type 2 diabetes mellitus. ProMining has
developed novel technology for the discovery of small molecules interfering in
protein-protein interactions that are clearly differentiated from conventional
small molecule drugs. This partnership will enable ProMining to expand the
exploitation of this technology by combining with the impressive global
research and development capabilities and resources of Roche," says Dr. Iris
Alroy, ProMining Therapeutics CEO.
About ProMining Therapeutics
ProMining Therapeutics, Ltd., based in Israel is a Van Leer Technology
Ventures Jerusalem and Pontifax portfolio company established in 2011 by Dr.
Silvia Noiman, Dr. Iris Alroy and Dr. Arnon Aharon and operating within the
Van Leer incubator. The company is a biopharmaceutical research and
development company engaged in the discovery and development of novel oral,
small-molecule drugs for a variety of indications including: cancer,
inflammation, chronic pain, cardiovascular and viral diseases.
The Company has developed CavitIIRx, a proprietary drug discovery and
development platform, focused on SH3 domain-mediated protein-protein
interactions, known to play a major role in numerous disease mechanisms.
ProMining's approach includes integration of state-of-the-art computational
analysis tools and novel biological assays directed towards identification of
small molecules blocking SH3-partnerinteraction. These tools are applied for
a fast discovery and development of SH3-partner inhibitors of different
targets, thereby creating a substantial pipeline.
Within a year from its incorporation ProMining was able to identify
protein-protein interfering small molecules for its oncology project. The
oncology project targets the ArgBP2-PAK1 SH3 domain mediated interaction.
ArgBP2 coordinates PI3K signaling of the PI3K/Akt/Bcl2 pathway, which plays a
detrimental role in many cancers.
Iris Alroy, Ph.D.
SOURCE ProMining Therapeutics Ltd
Press spacebar to pause and continue. Press esc to stop.